Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bone

Will breast cancer chemoprevention stand on 'solid bone'?

Nature Reviews Endocrinology volume 11, pages 138–139 (2015)Cite this article

Subjects

Aromatase inhibitors are the most effective agents for preventing breast cancer; however, their use is associated with bone loss and an increased risk of fractures. Sestak and colleagues show that administration of an oral bisphosphonate prevents aromatase-inhibitor-induced bone loss in postmenopausal women with osteopenia or osteoporosis who are at high risk of breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cuzick, J. et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383, 1041–1048 (2014).

    Article  CAS  Google Scholar 

  2. Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381–2391 (2011).

    Article  CAS  Google Scholar 

  3. Sestak, I. et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 15, 1460–1468 (2014).

    Article  CAS  Google Scholar 

  4. Ten Have, T. R. et al. Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr. Ann. 38, 772–783 (2008).

    Article  Google Scholar 

  5. Van Poznak, C. H. et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29, 1221–1227 (2011).

    Article  CAS  Google Scholar 

  6. Cameron, D. A. Breast cancer chemoprevention: little progress in practice? Lancet 383, 1018–1020 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

L.J.S. acknowledges research support from the NIH (R01 CA166060).

Author information

Authors and Affiliations

  1. University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, 72205, AR, USA

    Larry J. Suva & Issam Makhoul

Authors
  1. Larry J. Suva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Issam Makhoul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry J. Suva.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suva, L., Makhoul, I. Will breast cancer chemoprevention stand on 'solid bone'?. Nat Rev Endocrinol 11, 138–139 (2015). https://doi.org/10.1038/nrendo.2014.220

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.220

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer